At its Investor Conference on September 5, the Swiss Roche group has presented its development pipeline and given a clear commitment to personalized medicine: 72 new molecular entities are in the development and from 19 clinical trials in advanced stages, results are expected over the next 1 1/2 years. A total of more than 200 companion diagnostic projects are currently under development
The development pipeline is focused on oncology, and among other things, the conjugation of chemotherapeutic agents with antibodies is highlighted. So the first personalized treatment of the world, the antibody Trastuzumab (Herceptin), receives new tasks. Neurological, immunological and metabolic indications with high medical need are also on the list of Roche’s strategists. The antibody Gantenerumab against Alzheimer's disease, which is currently tested in the clinical phase III, is particularly interesting for the Munich scene because it was developed in a joint cooperation programme between Roche and the Munich’s biotech local hero MorphoSys
Roche Penzberg near Munich occupies a leading role in the strategy of personalized medicine: with approximately 4800 employees, this Roche site is the only worldwide on which both the pharma and the diagnostic division operate research, development and production. The pioneer of biotechnological production has established itself as an important driving force for the Munich biotech cluster m4.